Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (
The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive
| Agency | National Institutes of Health |
|---|---|
| Status | Posted |
| Opportunity number | PAR-25-055 |
| Posted date | 10/02/2024 |
| Application deadline | Jun 22, 2026 12:00:00 AM EDT |
| Award ceiling | none |
| Award floor | none |
| Who can apply | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); R |
| Assistance Listing (CFDA) | 93.853 |
| Description | The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. |
| Agency contact | grantsinfo@nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/356621 |